Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

ARTICLES

Payers, policies, and claims processing

November 2025—CAP TODAY publisher Bob McGonnagle spoke on Oct. 1, 2025 with Sarah Stewart of Telcor, which sells laboratory revenue cycle management software and services, and Jeanette Gray and Scott Rupnow of Pathology Associates of San Antonio and Pathology Reference Laboratory.

Scott Rupnow
Rupnow
Sarah Stewart
Stewart
Jeanette Gray
Gray

Read the article:

Bob McGonnagle: Jeanette Gray, tell us about your laboratory.

Jeanette Gray, vice president of revenue and payer relations, Pathology Associates of San Antonio and Pathology Reference Laboratory: We are a physician-owned practice in San Antonio and we operate a laboratory that does primarily anatomic pathology and women’s health testing. We have about 20-plus pathologists on staff. I joined the practice in July. Continue reading …

Watch the full conversation:

This roundtable discussion is sponsored by Telcor.

Building a better blood order, front to back

October 2025—For all the effort, redos, build-outs, planning, talking, and time that went into revamping blood product orders at Children’s Healthcare of Atlanta, the essence can be …

Sample flags, low anion gap—solving lab puzzles

October 2025—Speakers in a session at the ADLM meeting in July walked attendees through their real-life cases and quandaries that called for troubleshooting skill and left their laboratories with lessons learned from each. Offering up what they called lab adventures were Joe M. El-Khoury, PhD, DABCC, professor of laboratory medicine at Yale School of Medicine; Christopher Farnsworth, PhD, DABCC, associate professor of pathology and immunology at Washington University School of Medicine in St. Louis; and Reid Rosehill, MS, MLS(ASCP), laboratory manager at the University of California San Francisco.

The push for equity in CF carrier and newborn screening

October 2025—Bringing equity to cystic fibrosis carrier and newborn screening was the aim of expert groups that have released their recommendations for both. Carrier screening for 23 CFTR variants, which had been the recommended practice since 2004, was working well, “but only if a person was of white European or Ashkenazi Jewish ancestry,” said Karen Raraigh, MGC, CGC, assistant professor of genetic medicine at Johns Hopkins University. “It wasn’t working all that well because it was not an equitable test.” For people of Asian American and African American ancestry, she said, the detection rate was lower.

Unconventional tests raise stewardship questions

October 2025—Complementary and integrative medicine (CIM) has become gradually more popular and is accepted by a small but significant group of patients in tandem with traditional medicine. CIM providers often advocate a mix of conventional tests with special test panels that may include tens to hundreds of tests that conventional providers wouldn’t order. For those who lead laboratory stewardship efforts, it can be a challenge.

How far? How much? What labs say about digital path

October 2025—Glass or digital, onsite or remote—and what the rules are for the latter. That’s what Compass Group lab leaders talked about with CAP TODAY publisher Bob McGonnagle when they met online on Sept. 2. Here’s a glimpse into their digital pathology journeys. The Compass Group is an organization of not-for-profit IDN system laboratory leaders who collaborate to identify and share best practices and strategies.

New forensic pathology book offers best of all others

October 2025—CAP Publications has released its newest book, Forensic Pathology: Principles and Pitfalls. It comes more than 20 years after the second edition of the CAP Handbook of Forensic Pathology was published. The book’s more than 900 pages comprise 36 chapters written by 57 contributors. CAP TODAY asked the following questions of the editors—Joseph Prahlow, MD, and Erin Brooks, MD—who led the publication of the comprehensive update.

AMP case report: Unique patterns of BTK resistance: two independently arising resistance clones in response to covalent BTK inhibitor therapy in CLL/SLL

October 2025—Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a mature B-cell neoplasm composed of small atypical lymphoid cells that often coexpress CD5 and CD23 and are characterized by scant cytoplasm, clumped nuclear chromatin, and indistinct nucleoli. CLL/SLL can involve the peripheral blood, bone marrow, and various lymphoid tissues such as the lymph nodes, tonsils, and spleen, and it may occasionally present in extranodal locations as well.1 Within involved lymph nodes, pale-staining proliferation centers consisting of prolymphocytes or paraimmunoblasts are a characteristic finding in CLL/SLL.

Where court’s LDT decision leaves labs

September 2025—The Food and Drug Administration’s efforts to regulate laboratory-developed tests as medical devices came to a decisive halt this spring with a ruling from the U.S. District Court …

How a core lab took back its outpatient business

September 2025—Angela Vetch, MPH, DLM(ASCP), is tired of reading about large commercial labs buying hospital laboratories’ outreach business. “There is an alternative to that story,” said Vetch, director of laboratory services at Kootenai Health, a three-hospital system in Coeur d’Alene, Idaho.

MARKETPLACE

TRENDING